Glenmark Pharmaceuticals is in talks with some leading local and global drug makers, for the sale of its oral contraceptive product division, which manufactures generic anti-pregnancy medicine. The company has almost the entire range of about 19 variants of the oral contraceptive, which includes its existing product line and ANDAs pending approvals. The niche hormonal product is manufactured at the company's factory in Goa and has a market size of more than $2.5 billion in the US.
With few players managing to enter this segment due to its complex manufacturing technology, the product is a high-margin product. Further, Glenmark is the third company after Israel's Teva and American Actavis Inc with the capability of manufacturing this product.
Glenmark’s current portfolio consists of 90 products authorized for distribution in the US marketplace and 53 ANDA’s pending approval with the USFDA. In addition to these internal Filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1279.70 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2245.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: